ムラガキ ヨシヒロ   MURAGAKI Yoshihiro
  村垣 善浩
   所属   研究施設 研究施設
   職種   教授
論文種別 その他
言語種別 英語
査読の有無 査読あり
表題 Genetic Analysis in Patients With Newly Diagnosed Glioblastomas Treated With Interferon-Beta Plus Temozolomide in Comparison With Temozolomide Alone
掲載誌名 正式名:Journal of neuro-oncology
略  称:J Neurooncol
ISSNコード:0167594X/15737373
掲載区分国外
巻・号・頁 148(1),17-27頁
著者・共著者 NATSUME ,Atsushi†, AOKI Kosuke, OHKA Fumiharu, MAEDA ,Sachi, HIRANO Masaki, ADILIJIANG Alimu, MOTOMURA ,Kazuya, SUMI Minako, NISHIKAWA Ryo, NARITA Yoshitaka, MURAGAKI Yoshihiro, MARUYAMA Takashi, ITO ITO,Tamio, BEPPU Takaaki, NAKAMURA Hideo, KAYAMA Takamasa, SATO SATO,Shinya, NAGANE NAGANE,Motoo, MISHIMA Kazuhiko, NAKASU Yoko, KURISU Kaoru, YAMASAKI Fumiyuki, SUGIYAMA Kazuhiko, ONISHI Takanori , IWADATE Yasuo, TERASAKI Mizuhiko, KOBAYASHI Hiroyuki, MATSUMURA Akira, ISHIKAWA Eiichi , SASAKI Hikaru, MUKASA ,Akitake, MATSUO Takayuki, HIRANO Hirofum, KUMABE Toshihiro, SHINOURA Nobusada , HASHIMOTO Naoya, AOKI Tomokazu, ASAI Akio, ABE Tatsuya , YOSHINO Atsuo, ARAKAWA Yoshiki, ASANO Kenichiro, YOSHIMOTO Koji, SHIBUI Soichiro, OKUNO Yusuke, WAKABAYASHI Toshihiko, and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
発行年月 2020/05/04
概要 Purpose: This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone.
Experimental: DESIGN: Of 122 tumors, we performed deep targeted sequencing to determine the somatic mutations, copy number variations, and tumor mutation burden; pyrosequencing for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation; Sanger sequencing for the telomerase reverse transcriptase (TERT) promoter; and microsatellite instability (MSI) testing in 95, 91, 91 and 72 tumors, respectively. We performed a multivariable Cox regression analysis using backward stepwise selection of variables including clinical factors (sex, age, performance status, residual tumor after resection, tumor location) and genetic alterations.
DOI 10.1007/s11060-020-03505-9
PMID 32367437